On October 23rd, 2014, we updated our
By continuing to use LinkedIn’s SlideShare service, you agree to the revised terms, so please take a few minutes to review them.
Acquired hemophiliaTable 1. Clinical conditions associated with acquired FVI-II/FIX inhibitors. The mortality is high with the majority of deaths occurring within the first weeks after presentation. TheClinical Green Morrison Bossi Baudo high rate of death may be related to inappropriate inva-conditions D1 AE3 P8 F9 % % % % sive procedures (in the Italian Registry of Acquired Hemophilia [Registro Italiano Emofilia Acquisita - RIEA], 1/3 of the events occurred after surgery) carried out toNumber of patients 215 65 34 96 control the bleeding, to a delay in diagnosis and to inad-Idiopathic 46.1 52.5 47.1 46.8 equate replacement therapy.9Autoimmune 20.4 21.5 17.6 16.6 Bleeding was controlled by replacement therapy with disorders porcine FVIII concentrate. On day 7, while on treatment,Drug related 3.0 5.6 2.9 0 the patient suffered an extensive hematoma of the chest wall. The APTT ratio was 1.9. The patient was treatedPregnancy and 11.0 7.3 8.9 21.0 post-partum with FEIBA and the bleeding subsided. On day 15 hematemesis and melena secondary to a bleeding duo-Malignancies 13.5 5.5 14.6 9.4 denal ulcer, confirmed by gastroscopy, occurred;Other 1.5 11.8 8.8 6.2 immuno-adsorption with Sepharose protein A and replacement therapy with porcine FVIII were successful. On day 30 the patient died because of the recurrence ofpearance of the inhibitor; if therapy is effective low massive hematemesis. At autopsy the source of thetiter inhibitors, especially in the early stages, are more bleeding was identified as a small artery.likely to disappear than high titer ones.19–21 Our patient had been on steroids for one year because Therapeutic optionsof a polymyalgia-syndrome; the etiology and pathogen-esis are not well understood but its relevance to the The aims of therapy are to control the bleeding andappearance of the anti FVIII inhibitor is questionable. suppress the inhibitor. The diagnosis of AH is suggested by the clinical pic-ture and confirmed by the laboratory tests. Usually Therapy to control the bleedingsevere bleeding or diffuse bruising occurs either spon- No prospective randomized trials comparing the effi-taneously or following minor trauma or after a proce- cacy of various agents have been reported and none ofdure (positioning of an intravenous catheter, surgery, the available agents is effective in all patients. Efficientintramuscular injections). Common sites of bleeding are hemostasis can be achieved with a variety of methods:the skin (large ecchymoses), the mucosae (epistaxis, gin- normalization/correction of FVIII (human plasma-givorrhagia, metrorrhagia), and the muscles; hem- derived or recombinant FVIII concentrates, porcine con-arthoses are unusual.3,8,19-21 If the bleeding occurs in crit- centrate, desmopressin), bypassing the inhibitor [acti-ical sites, compression problems may ensue. Retroperi- vated prothrombin complex concentrate (FEIBA),toneal hemorrhages are common and, if unrecognized, recombinant activated FVII (rFVIIa)], neutralization ofcan be fatal. the inhibitor by idiotypic anti FVIII antibodies (high dose In our patient the space-occupying image interpreted immunoglobulins), and removal of the inhibitor by im-as an aneurysm was in fact due to a hematoma of the munoadsorption or plasmapheresis. Combined modali-ileo-psoas muscle. The diagnosis might have been con- ties may be necessary. The selection criteria for the anti-sidered if the APTT ratio had not been overlooked. hemorrhagic therapy are site and entity of bleeding, A prolonged APTT, not corrected by incubation with age, underlying disorders, co-morbid states, inhibitornormal plasma, with a normal prothrombin time is the titer, and cross-reactivity with porcine FVIII. Life-orhallmark of the laboratory diagnosis. Lupus anticoag- limb-threatening bleeding must be treated aggressive-ulant (LA) and heparin in the plasma must be exclud- ly. In minor bleeding (e.g. ecchymoses) observation ised. The presence of heparin is suggested by a pro- justified. The bleeding-related mortality rate approach-longed thrombin time with normal reptilase time. The es 15%, mainly due to early hemorrhagic complications;diagnosis is confirmed by the specific factor assay and this fact underscores the importance of early diagnosisby dosage of the inhibitor.2,11,12 The measurement of and treatment. The therapeutic agents and the recom-antiporcine factor VIII inhibitor is recommended. The mended doses are reported in Table 2.inhibitor titer is poorly correlated with the clinical pic- For minor bleeds with low inhibitor titers (<10 BU/mL)ture;8 therefore it is less valuable in guiding therapy replacement with human FVIII concentrate is the treat-than it is in patients with congenital hemophilia and ment of choice.11,12,22 In AH, the anamnestic response isinhibitor. A laboratory diagnostic algorithm is report- rare.17,18,23-26 The recovery and half-life of the infused FVI-ed in Figure 2. II cannot be predicted because of the variable kinetics haematologica 2004; 89(1):January 2004 97
F. Baudo et al. tained response. The cost of this treatment is high. rFVIIa has been a major advance in the treatment of bleeding in congenital hemophilia with high titer inhibitors (>10 BU/mL); however, efficacy and safety in AH are not well defined. Favorable reports in patients who failed to benefit from other treatments suggest that it could be used as first-line therapy. Disadvan- tages are its high cost, the lack of laboratory monitor- ing and its short half-life (6 hours) necessitating fre- quent administrations; thromboembolic complications are rare.31-34 The mechanism of action of bypassing concentrate (FEIBA) is not fully understood. Efficacy is not predictable and laboratory monitoring is not satisfactory.35-37 Only clinical endpoints can be used to monitor treatment. Thromboembolic complications are possible.38 FVIII autoantibodies have a low cross-reactivity with porcine FVIII; therefore a satisfactory hemostatic level may be obtained even in patients with high inhibitor titer.39-42 Pyrexia, flushing, urticaria may occur during the initial infusion; severe anaphylactic reactions or throm- bocytopenia are rarely observed with concentrates obtained by serial polyelectrolyte fractionation.43–46 The porcine FVIII concentrate is not available in Italy. In particular clinical conditions (e.g. prior to surgery) effective hemostasis can be restored by removing the inhibitor by plasmapheresis or by immunoadsorption (staphylococcal protein A bound to sepharose or to sil- ica matrix, sepharose-bound polyclonal sheep antihu- man antibodies). Extracorporeal methods have only a temporary effect and replacement therapy with FVIII is needed immediately after the procedure. Simultaneous immunosuppression is needed because of the subse- quent rebound in inhibitor titer. The need for special equipment and expertise limit its use but in the case ofFigure 2. Laboratory algorithm for the diagnosis of FVIII life-threatening hemorrhages, immunoabsorption mayinhibitor. be lifesaving.47-51 Immunosuppressive therapyof FVIII.2,5 Nevertheless its determination is clinically The aim of immunosuppressive therapy is to suppressuseful. A loading dose is given to neutralize the inhibitor of the inhibitor. Factors predicting a positive responseand subsequent doses are then given by bolus or by are a low inhibitor level and a short interval betweencontinuous infusion to achieve and maintain the hemo- the appearance of the inhibitor and the start of thera-static level.25,26 Many FVIII concentrates with compara- py.11,12,52,53 Prednisone, cyclophosphamide, azathioprine,ble therapeutic efficacy and safety are commercially vincristine, and cyclosporine are all currently used asavailable. monotherapy or in combination. There are no prospec- DDAVP (1-deamino-8-D-arginine) infusion results in tive, controlled clinical trials to evaluate their efficacy.a rapid increase of FVIII which is sufficient to treat The available studies are retrospective and include aminor bleeding.27-29 The tachyphylaxis phenomenon lim- limited number of patients with different clinical con-its its use to 3 or 4 consecutive days. The well-known ditions. On the other hand it would be difficult to car-antidiuretic and vasomotor side-effects should be care- ry out sufficiently powered prospective, controlled stud-fully considered in older patients.11,29 ies to evaluate the efficacy of the different therapeutic High dose immunoglobulins induce complete or par- agents. Efficacy is also difficult to assess because of thetial remission in 23-37% of the patients with low titer possibility of spontaneous remissions (mainly in chil-inhibitors.30 Multiple courses are needed to obtain a sus- dren, post partum or drug-associated cases).6,13 Severe 98 haematologica 2004; 89(1):January 2004
Acquired hemophiliaTable 2. Agents used and recommended dose in the treat- weeks induces inhibitor disappearance in 1/3 of thement of acute bleeding in acquired hemophilia. patients, generally in those with low titer inhibitors, but that sustained remission after prednisone discontinua-Agents Initial dose Subsequent doses tion is rare; cyclophosphamide (2 mg/kg per day) com- bined with prednisone and/or vincristine, azathioprine,Human FVIII 50-100 IU/kg 50-75 IU/kg 2-3 times/ day induces complete and continuous remissions in a high or 4-14 U/kg/h by c.i. percentage of cases (78-92%) provided that the ther-Porcine FVIII 50-100 IU/kg 50-75 IU/kg 2-3 times/ day apy is continued until the inhibitor disappears com- or 4-14 U/kg/h by c.i. pletely and that it is administered at adequate dos-rFVIII 50-100 IU/kg 50-75 IU/kg 2-3 times/ day es.11,12,52 Previous experience in hemophiliacs emphasized or 4-14 U/kg/h by c.i. the importance of carrying out the treatment accord- ing to hematologic tolerance.58DDAVP 0.3 µg/kg 0.3 µg/kg/day Immune tolerance is an accepted and effective treat-High dose Ig 1 or 0.4 g/kg 1 or 0.4 g/kg for 2 or 5 ment in patients with congenital hemophilia and consecutive days inhibitor but has rarely been applied in AH. Evidence ofAPCC 50-100 IU/kg 50-75 IU/kg 2-3 times/ its effectiveness and safety was provided by the day or c.i. Budapest protocol (human FVIII combined with cyclophosphamide and methylprednisolone).59 A com-rFVIIa 90 µg/kg 90 µg/kg every 3-6 hours or plete and sustained remission was reported in more 10-20 µg/kg/h by c.i. than 90% of the patients. Similar results were report- ed by the Heidelberg and Bonn groups which used a modified Malmö protocol (immunoadsorption, highand life-threatening hemorrhages may occur in 80-90% doses of FVIII, cyclophosphamide and corticosteroids).60,61of patients in the course of the disease, suggesting that Very recently promising results have been reported withimmunosuppressive therapy must be started as soon as the anti-CD20 monoclonal antibody (rituximab)62,63 andthe diagnosis is established.54,55 2-chlorodeoxyadenosine.64 Immunosuppressive treatment with steroids alone is The majority of cases of acquired hemophilia occur inthe initial preferred treatment. In children, in post-par- general hospitals and bleeding manifestations may betum women and in drug-associated cases complete dis- life-threatening. In the presence of an unexplainedappearance of the inhibitor was reported in 33-96% of often severe hemorrhage with an abnormally prolongedthe patients.1,9,56,57 The patients unresponsive to steroids APTT it is important to seek immediate specialist advice.were treated with chemotherapeutic agents alone or A prolonged APTT is often observed and overlooked.combined with steroids with an overall response rate of Because of the rarity of the disorder, the complex treat-58-80%.1,9,57 The relapse rate averaged 23% but a sec- ment and the potential risk of severe bleeding, theseond remission was obtained in 90% of the patients with patients should be managed in the hemophilia centerscombined therapy.9,56 Different strategies may be suit- or under their supervision.able for different subgroups of patients.3 A watch and Received on April 11, 2003; accepted on November 30,wait approach may be appropriate for children, preg- 2003.nancy-related and drug-associated cases; combinedimmunosuppressive therapy is indicated for idiopathic, Addendumautoimmune and malignancy-related cases. Current The European Registry on Acquired Hemophilia hasevidence from the literature suggests that prednisone recently been activated on Internet: www.eachreg-at a dose of > 1 mg/kg per day for a minimum of three istry.org.References Immunological characterization of fac- Acquired factor VIII and factor IX tor VIII inhibitors. In: Hoyer LW, editor. inhibitors: survey of the Italian Haemo- 1. Green D, Lechner K. A Survey of 215 non- Factor VIII inhibitors. New York: Liss; philia Centers (AICE). Register of haemophilic patients with inhibitors to 1995. p. 73-85. Acquired factor VIII/IX inhibitors. Haema- factor VIII. Thromb Haemost 1981;45: 6. Lottenberg R, Kentro TB, Kitchens CS. tologica, 2003;88 Suppl 12:93-9. 200-3. Acquired haemophilia. A natural history 10. Ludlam CA, Morrison AE, Kessler C. Treat- 2. Hoyer LW. Factor VIII inhibitors. Curr Opin study of 16 patients with factor VIII ment of acquired hemophilia. Semin Hematol 1995;2:365-71. inhibitors receiving little or no therapy. Hematol 1994;31 Suppl 4:16-9. 3. Morrison AE, Ludlam CA. Acquired hae- Arch Intern Med 1987;147:1077-81. 11. Kessler CM, Nemes L. Acquired inhibitors mophilia and its treatment. Br J Haema- 7. Shapiro SS, Hultin M. Acquired inhibitors to factor VIII. In: “Inhibitors in patients tol 1995;89:231-6. to blood coagulation factors. Sem with Haemophilia”. Rodriguez-Merchan 4. Di Bona E, Schiavoni M, Castaman G, Thromb Haemost 1975;1:336-85. EC, Lee C, editors. Blackwell Science Ltd. Ciavarella N, Rodeghiero F. Acquired 8. Bossi P, Cabane J, Ninet J, Dhote R, Hans- Oxford; 2002. p. 98-112. hemophilia: experience of two Italian lik T, Chosidow O, et al. Acquired hemo- 12. Ewenstein BM, Putnam KG, Bohn RL. centers with 17 new cases. Haemophilia philia due to factor VIII inhibitors in 34 Nonhemophilic inhibitors of coagulation. 1997;3:183-8. patients. Am J Med 1998;105:400-8. In: Kitchens CS, Alving BM, Kessler CM, 5. Hoyer LW, Gawryl MS, de la Fuente B. 9. Baudo F, Mostarda G, De Cataldo F. editors. Consultative Hemostasis and haematologica 2004; 89(1):January 2004 99
F. Baudo et al. Thrombosis. Elsevier Science, WB Saun- 31. Hay CR, Negrier C, Ludlam CA. The treat- Factor VIII inhibitors. New York. Alan R. ders Co: Philadelphia; 2002. p. 75-90. ment of bleeding in acquired haemophil- Liss, 1984:225-41.13. Hauser I, Schneider B, Lechner K. Post- ia with recombinant factor VIIa: a multi- 48. Négrier C, Dechavanne M, Alfonsi F, partum factor VIII inhibitors. A review of center study. Thromb Haemost 1997;78: Tremisi PJ. Successful treatment of the literature with special reference to 1463-7. acquired factor VIII antibody by extracor- the value of steroid and immunosuppres- 32. Arkin S, Cooper HA, Hutter JJ, Miller S, peal immunoadsorption. Acta Haematol sive treatment. Thromb Haemost 1995; Schmidt HL, Seibel NL, et al. Activated 1991;85:107-10. 73:1-5. recombinant human coagulation factor 49. Gjörstrup P, Berntorp E, Larsson L, Nilsson14. Coller BS, Hultin MB, Hoyer LW, Miller F, VII therapy for intracranial hemorrhage IM. Kinetic aspects of removal of IgG and Dobbs JV, Dosik MH, et al. Normal preg- in patients with Haemophilia A or B with inhibitors in hemophiliacs using protein A nancy in a patient with prior post-par- inhibitors. Haemostasis 1998;28:93. immunoadsorption. Vox Sang 1991;61: tum factor VIII inhibitor: with observa- 33. Scharrer I. Recombinant factor VIIa for 244-50. tions on pathogenesis and prognosis. patients with inhibitors to factor VIII or IX 50. Knöbl P, Derfler K. Extracorporeal immu- Blood 1981;58:619-24. deficiency. Hemophilia 1999;5:253-9. noadsorption for the treatment of hae-15. Neihardt B, Bartels O, Hahn B. Hemmkör- 34. Baudo F, Gaidano G. Recombinant acti- mophilic patients with inhibitors to fac- perhaemophilie A post-partum. Dtsch vated factor VII (rFVIIa) for the treatment tor VIII or IX. Vox Sang 1999;77 Suppl Med Wochenschr 1985;110:799. of bleeding secondary to acquired factor 1:57S-64S.16. Michiels JJ, Hamulyak K, Nieuwenhuis VIII inhibitor. Blood 2002;11:[Abstract 51. Jansen M, Schmaldienst S, Banyai, Que- HK, Novakova I, van Vliet HHDM. Acquir- 3877]. henber P, Pabinger I, Derfler K, et al. Treat- ed haemophilia A in women postpartum: 35. Lusher JM, Shapiro SS, Palascak JE, Rao ment of coagulation inhibitors with management of bleeding episodes and AV, Levine PH, Blatt PM. Efficacy of pro- extracorporeal immunoadsorption (Ig natural history of the factor VIII inhibitor. thrombin complex concentrates in Therasorb). Br J Haematol 2001;112:91-7. Eur J Haematol 1997;59:105-9. haemophiliacs with antibodies to factor 52. Feinstein DI, Green D, Federici AB, Good-17. Baudo F. Acquired Factor VIII (FVIII) VIII. A multicentre therapeutic trial. N night SH. Diagnosis and management of inhibitors in pregnancy: data from the Engl J Med 1980;303:421-5. patients with spontaneously acquired Italian Haemophilia register relevant to 36. Turecek PL, Varadi K, Gritsch H et al. Fac- inhibitors of coagulation. ASH Meeting; clinical practice. Br J Obstet Gynaecol tor Xa and prothrombin: mechanism of Haematology. 1999. p. 192-208. 2003;110:1-4. action of FEIBA. Vox Sang 1999;77 Sup- 53. Hay CRM, Colvin BT, Ludlam CA, Hill FGH,18. Solymoss S. Post partum acquired factor pl 1:72S-9S. Preston FE. Recommendations for the VIII inhibitors: results of a survey. Amer J 37. White IIGC. Seventeen years’ experience treatment of factor VIII inhibitors: from Hematol 1998,59:1-4 with Autoplex/Autoplex T. Evaluation of the UK Haemophilia Center Directors’19. Hauser I, Leckner K. Solid tumors and FVI- inpatients with severe haemophilia A and Organisation Inhibitor Working Party. II antibodies. Thromb Haemost 1999; 82: factor VIII inhibitors at a major haemo- Blood Coagul Fibrinolysis 1996;7:134-8. 1005-7. philia center. Haemophilia 2000;6:508- 54. Hay CRM. Acquired hemophilia. Baillière’s20. Sallah S, Nguten NP, Abdallah JM, Han- 12. Clin Haematol 1998;11:287-303. rahan LR. Acquired hemophilia in patients 38. Chavin SI, Siegel DM, Rocco TA, Olson JP. 55. Rubinger M, Rivard GM, Teitel J, Walker with hematologic malignancies. Arch Acute myocardial infarction during treat- IL. Suggestions for the management of Pathol Lab Med 2000; 124:730-4. ment with an activated prothrombin factor VIII inhibitors. Haemophilia 2000;621. Sallah S, Wan JY. Inhibitors against fac- complex concentrate in a patient with Suppl 1:52S-9S. tor VIII in patients with cancer. Cancer factor VIII deficiency and a factor VIII 56. Spero JA, Lewis JH, Hasiba U. Corticos- 2001;91:1067-74. inhibitor. Am J Med 1988; 85:245-9. teroid therapy for acquired FVIII:C22. Cohen AJ, Kessler CM. Acquired inhibitors. 39. Morrison AE, Ludlam CA, Kessler CM. Use inhibitors. Br J Haematol 1991;48:636- In: Lee CA, editor. Haemophilia. Baillière’s of porcine factor VIII in the treatment of 42. Clin Hematol 1995;9:31-54. patients with acquired hemophilia. Blood 57. Green D, Rademaker AW, Briet E. A23. Kessler CM. An introduction to factor VIII 1993;81:1513-20. prospective randomized trial of pred- inhibitors. The detection and quantita- 40. Gribble J, Garvey MB. Porcine factor VIII nisolone and cyclophosphamide in the tion. Am J Med 1991;91 Suppl 5A:33-6. provides clinical benefit to patients with treatment of patients with factor VIII24. Blatt PM, White IIGC, McMillan CW, high levels of inhibitors to human and antibodies. Thromb Haemost 1993;70: Roberts HR. Treatment of antifactor VIII porcine factor VIII. Haemophilia 2000;6: 753-7. antibodies. Thromb Haemost 1977;38: 482-6. 58. Bussi L, Baudo F, de Cataldo F. Factor VIII 514-23. 41. Bona RD, Ribeno M, Klatsky AV, Panek S, concentrate and cyclophosphamide in25. Kasper CK. The therapy of factor VIII Magnifico H, Rickles FR. Continuous infu- patients with factor VIII inhibitors. Blood inhibitors. Prog Hemost Thromb 1989; sion of porcine FVIII for the treatment of 1974;44:767. 9:57-86. patients with factor VIII inhibitors. Semin 59. Nemes L, Pitlik E. New protocol for26. Lusher JM. Use of factor VIII by-passing Hematol 1993;Suppl 1:30-2. immune tolerance induction in acquired agents to control bleeding in patients 42. Kessler CM, Ludlam CA. The treatment of hemophilia. Haematologica 2000;85 with acquired factor VIII inhibitors. In: acquired factor VIII inhibitors: worldwide (Suppl. to 11):64-8. Kessler CM, editor. Acquired hemophilia. experience with porcine factor VIII con- 60. Huth-Kuhne A, Ehrenforth S, Scharrer I, Excerpta Medica; 2nd ed. 1995. p. 113-29. centrates. Semin Hematol 1993;30:22-7. Zimmermann R. A new treatment option27. De la Fuente, Panek S, Hoyer LW. The 43. Hay CRM, Bolton-Maggs P. Porcine factor for patients with acquired hemophilia A. effect of 1-deamino 8 D-arginine vaso- VIIIC in the management of patients with The modified Malmö-Heidelber protocol. pressin (DDAVP) in non-haemophilic factor VIII inhibitors. Transfus Med Rev Thromb Haemost 2001;86: 3364a patient with an acquired type II inhibitor. 1991;5:145-51. [abstract]. Br J Haematol 1985;59:127. 44. Gatti L, Mannucci PM. Use of porcine fac- 61. Hess L, Zeitler H, Unkrig Ch, Nettekoven28. Naorose-Abidi SM, Bond LR, Chitolie A, tor VIII in the management of seventeen W, Albert T, Schwaab R, et al. Modified Bevan DH. Desmopressin therapy in patients with factor VIII antibodies. Bonn-Malmö protocol (MBM-P) Haema- patients with acquired factor VIII Thromb Haemost 1984;51:379-84. tologica 2003;88 Suppl 12:78-85. inhibitors. Lancet 1988;1:366. 45. Gringeri A, Santagostino E, Tradati F. 62. Karwal MW, Schlueter AJ, Zenk DW, Davis29. Muhm M, Grois N, Kier P, Stumpflen A, Adverse effects of treatment with porcine RT. Treatment of acquired factor VIII defi- Kyrle P, Pabinger I, et al. 1-Deamino-8-d- FVIII. Thromb Haemost 1991;65:245-7. ciency with rituximab. Blood 2001;98: arginine vasopressin in the treatment of 46. Morrison AE, Ludlam CA. The use of 533a[Abstract]. non- haemophilic patients with acquired porcine factor VIII in the treatment of 63. Wiestener A, Cho HJ, Asch AS, Michelis factor VIII inhibitor. Haemostasis 1990; patients with acquire haemophilia: the MA, Zeller JA, Peerschke EIB et al. Ritux- 20:15. Unites Kingdom experience. Am J Med imab in the treatment of acquired factor30. Schwartz RS, Gabriel DA, Aledort LM, 1991;91 Suppl 5a:27S-36S. VIII inhibitors. Blood 2002;100:3426-8. Green D, Kessler CM. A prospective study 47. Nilsson I, Sundqvist S-B, Freiburghaus C. 64. Sallah S, Wan JY. Efficacy of 2-chloro- of acquired (autoimmune) factor VIII Extracorporeal protein A sepharose and deoxyadenosine in refractory factor VIII inhibitors with high-dose intravenous specific affinity chromatography for inhibitors in persons without hemophilia. gammaglobulin. Blood 1995;86:797-804. removal of antibodies. In: Hoyer LW, ed. Blood 2003;101:943-5. 100 haematologica 2004; 89(1):January 2004